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Abstract 
 
Background 
Increasing numbers of nurses, pharmacists and allied health professionals across the world 
have prescribing rights for medicines: over 90,000 of the eligible United Kingdom workforce 
are qualified as non-doctor prescribers. In order to inform future developments, it is 
important to understand the benefits and impact of prescribing by allied health professionals 
including physiotherapists and podiatrists. 
Aim: to compare outcomes of physiotherapist and podiatrist Independent Prescriber (PP- IP) 
patients with those of physiotherapist and podiatrist non-prescribers (PP-NPs). Outcome 
measures included patient satisfaction, ease of access to services, quality of life and cost 
implications. 
Design: a mixed method comparative case study  
Methods: Using mixed methods of data collection, outcomes were compared between 7 sites 
where care was provided from a PP-IP (3 podiatrist and 4 physiotherapist IPs) and 7 sites from 
a PP-NP (3 podiatrist and 4 physiotherapist NPs). Patients were followed up for 2 months 
(2015-2016).  
Results:  489 patients were recruited:  n=243 IP sites, and n=246 NP sites. Independent 
prescribing was found to be highly acceptable, and equivalent in terms of quality of life 
(p>0.05) and patient satisfaction (p≤0.05) compared to care provided by NPs. PP-IP care 
delivery was found to be more resource intensive than PP-NP, with longer consultation 
duration for IPs (around 6.5 mins), and a higher proportion of physiotherapy patients 
discussed with medical colleagues (around 9.5 minutes).   
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Conclusion 
This study provides new knowledge that PP-IPs provide high levels of care. PP-IP care 
delivery was found to be more resource intensive. Further research is required to explore 
cost effectiveness. A more focussed exploration within each profession using targeted 
outcome measures would enable a more robust comparison, inform future developments 
around the world and help ensure non-doctor prescribing is recognised as an effective way 
to alleviate shortfalls in the global workforce.  
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Background 
As life expectancy increases, and the world’s population continues to grow 1-3, many countries 
are shifting the focus of their health system from acute to chronic diseases, alongside 
managing increasing service demands 4. Recent data from the United Kingdom (UK), United 
States (US) and across Europe confirms 25% of adults take three or more medicines each day 
2, 5 and that by 2020 the world’s population will receive 4.5 trillion doses of medicine each 
year 5-7.  
 
There is however, a worldwide deficit of 18 million health workers 8, with a predicted 350,000 
shortfall in the UK, and a third of the current workforce due to retire by 2030 9. Inadequacies 
with traditional doctor/physician-led care systems mean that in order to maintain patient 
access to prescription medicines, new approaches are imperative 9, 10.  Allied Health 
Professionals, (health professionals who are not medical doctors, physicians, nurses. 
pharmacists or dentists), e.g. therapeutic radiographers, paramedics, podiatrists and 
physiotherapists (AHP) have in particular been identified as having an integral role to the 
required transformational change 11.  
 
Extending prescribing rights to nurses, pharmacists and allied health professions 12, 13 has 
been the focus of a UK policy drive to improve services and access to medicines by making 
better use of existing skills and support service innovation 11, 14-16. Of the 907,000 UK 
healthcare professionals entitled to undertake prescribing training 17, over 90,000 of the 
eligible workforce are now qualified as prescribers 17, placing the UK as the forerunner in the 
development of non-doctor prescribing, also known as non-medical prescribing, worldwide. 
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In the UK, Independent Prescribing (IP) and Supplementary Prescribing (SP) are two different 
forms of non-doctor prescribing. Training typically involves 27 classroom days, a mandatory 
aspect of supervised practice, and robust academic and practice assessment 18-20 , a dual 
qualification in IP and SP being awarded to registered nurses, pharmacists, radiographers and 
paramedics, podiatrists and physiotherapists.  Supplementary prescribing rights were 
extended to some allied health professions in 2005, with further changes to legislation in 2013 
permitting physiotherapists and podiatrists to prescribe medicines independently 21-23. Apart 
from some restrictions around independent prescribing of controlled drugs and in line with 
other allied health professions, physiotherapists and podiatrists, normally with 3 years 
relevant post qualification experience, are able to independently prescribe any medicine 
within their area of competence without the need for a doctor. By contrast supplementary 
prescribing defined as dependent prescribing, is based on an initial diagnosis by a doctor and 
an agreed clinical management plan detailing medicines that can be prescribed 24. 
 
Although several other countries, including Australia, Ireland, and Netherlands, have seen 
similar developments in non-medical prescribing, approaches to training, accreditation and 
models of prescribing practice are varied 25-28.  Physiotherapists have for example, 
authorisation to provide advice about and/or to administer or supply medicines in some 
states in Australia, New Zealand and Canada, but only those in the US military can prescribe 
29, 30.  Podiatrists have similar authority in Australia and some European countries but are only 
entitled to prescribe in some Canadian provinces 29, 31.  
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When used by nurses and pharmacist, independent and supplementary prescribing are 
reported as acceptable and beneficial to patients, with some evidence of enhanced clinical 
outcomes compared to doctors  26, 32-34. A recent systematic review reported that non-medical 
prescribing has no adverse impact upon patient outcomes, patient satisfaction or resource 
utilisation 35.  Reviews on the impact of extended physiotherapist roles reveal research 
hampered by small numbers, role variation and poor role definition 36, 37, literature dominated 
by service descriptions and audit with positive reporting bias 29, 36, 37, and a lack of evidence 
regarding podiatric practice 29. Whilst physiotherapist and podiatrist supplementary 
prescribing helps streamline service delivery 38, 39, independent prescribing is expected to 
bring additional benefits in line with nurse and pharmacist prescribing 40, 41.  Exploration of 
clinical and cost effectiveness in this area is limited with inconclusive findings 42-47. As most 
evidence relates to nurses and pharmacists, it is important to evaluate the impact of 
prescribing by allied health professionals in order to inform commissioning and 
implementation of non-medical prescribing services where they are beneficial.  
 
Seven years after the introduction of current legislation enabling physiotherapists and 
podiatrists to independently prescribe medicines, there were (as of October 2020) 1,295 
physiotherapists and 442 podiatrists with an annotation as independent prescriber, with a 
further 108 physiotherapists and 67 podiatrists registered as supplementary prescribers 48. 
There is a lack of evidence of reporting on physiotherapist and podiatrist independent 
prescribing practice, or the medicines they prescribe and no studies available which quantify 
the impact of podiatrist and physiotherapist independent prescribing on patient satisfaction, 
access to services, quality of life or report cost-implications of care delivery 29 . This is 
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important given the increasing emphasis in the UK and around the world on extending 
prescribing rights to nurses, pharmacists and allied health professionals as a key strategy in 
addressing workforce deficits and ensuring patients have ongoing access to medicines 8-10, 49. 
 
Methods 
Aim: was to compare the outcomes of patients managed by physiotherapist and podiatrist 
independent prescribers (PP- IP) with those under the care of physiotherapist and podiatrist 
non-prescribers (PP-NPs). Outcome measures included patient satisfaction, ease of access to 
services, quality of life and costs.  
 
Study Design  
This study was commissioned to undertake concurrent evaluation of physiotherapist and 
podiatrist independent prescribing reflecting  the 2013 regulatory changes introduced to both 
professions.   A comparative case study methodology used in situations when no single 
outcome measure is available was adopted 50, 51. Outcomes were compared between 7 sites 
where patients received care from a PP-IP (3 podiatrist and 4 physiotherapist IPs) and 7 sites 
where care was provided by a PP-NP without a prescribing qualification (3 podiatrist and 4 
physiotherapist non-prescribers) 52. Mixed methods (including interviews, structured 
observation of consultations, patient questionnaires) were used to collect data at each of the 
14 sites during a 5-day period of observation of practice. Details of data collection tools, 
methods and piloting are shown in Table 1. 
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The original intention was to collect data on patient follow-up treatments and re-
consultations by audit of clinic records at 2 months.  It was evident that this was limited and 
inconsistent during data collection at the first four sites.  The protocol was therefore amended 
to include a second patient questionnaire for self-report usage of health services in the 2 
months after the index consultation. Data collection took place simultaneously January 2015-
March 2016.  
 
Insert Table 1 here 
 
Sample size 
Anticipating patient satisfaction and ease of access to services being best expressed as 
positive or negative responses, in order to detect an absolute underlying difference of 40% 
between PP-IP and NP-PP, with size = 5% and power = 80%, a minimum of 24 subjects were 
needed in each PP-IP and NP-PP site. Allowing for a dropout rate of 20%, to enable a 
statistically sound comparison to be made between any specific pair of PP-IP and NP-PP sites, 
a target recruitment of 30 patients per site (total n=420), collected over a maximum of 5 
working days, was set.  
Initial sample estimates, based on information provided by physiotherapists and podiatrists 
in clinical practice, indicated that full-time PP-IPs/NP-PPs have up to 60 consultations, lasting 
approximately 20-40 minutes each, per week, generating data on potentially 840 patient care 
episodes across 14 sites, indicated that, even allowing for repeat patient visits and inclusion 
criteria failures, such a recruitment was feasible. 
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Case sites: Sites with physiotherapist and podiatrist independent prescribers were 
purposively selected from an earlier study phase 52 to include diversity with respect to care 
setting, geographical location and patient demographics across England. 
 
Recruitment 
Podiatrists and Physiotherapists  
Initial email/ telephone contact was made with physiotherapist and podiatrist independent 
prescribers who had completed an earlier survey whilst undertaking independent prescribing 
training (n=70) and indicated willingness to participate in further research 52. Those who 
expressed an interest were provided with a participant information sheets and 
supplementary information on case site involvement and requested to ensure organisational 
and local Research and Development support. 
 
Non-prescribing physiotherapist and podiatrist sites, matched on professional role, care 
setting, geographical location and using NHS Agenda for Change (Afc)  national pay scale 
banding 53, were either nominated by PP-IPs, identified through personal contacts of the 
project advisory group or enquiries from individual Research and Development departments 
via the National Institute of Health Research (NIHR) portfolio.  These matched NP-PPs were, 
with consent, contacted by a member of the research team and recruited following the same 
process as for PP-IPs.  Written informed consent was taken from PP-IPs and NP-PPs on the 
first day of each case site visit by JE, who assured on-going consent with each PP-IP or NP- PP 
at the beginning of each contact day.  
 
Patients 
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At each case site a consecutive sample of patients who had scheduled appointments with 
physiotherapist and podiatrist independent prescribers/ non-prescribers providing adult 
services during a 5-day (up to 37hrs) site visit by the study researcher (JE) were recruited in 
NHS sites by trained research nurses, and private sites by a second study researcher (EK) 
between March 2015 and February 2016. Informed written consent was obtained from those 
who were willing to participate. 
 
A screening log of all patients approached for participation in the study (n=563) was recorded; 
both those recruited to the study (n=488, 86.7%) and those declining participation 
(n=75,13.3%), including hospital/unit medical record numbers, gender and the date of 
consent, by the local research nurse/ study researcher. Following the observed consultation 
(see table 1) those who agreed to participate completed and posted Patient Questionnaire 1 
into a box in the clinic area or returned using pre-paid envelopes.  
 
Data collection 
An initial telephone interview, informed by previous work in the area 54 was conducted with 
the physiotherapist and podiatrist from each site using semi-structured questions to gather 
information on site characteristics, and professional role. Details of the data collection and 
instruments, informed by the study patient and public involvement and advisory groups, are 
presented in Table 1. All data collection instruments were piloted in a non-study 
physiotherapist independent prescriber NHS outpatient clinic in January 2015, with only 
minor corrections to wording required (see Table 1). 
 
Outcome measures 
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Baseline Questionnaire 1: Informed by previous work 54 and several validated tools  55-61 a 
patient questionnaire was constructed to ensure that the generic questionnaire developed 
to evaluate prescribing by nurses and midwives in the Republic of Ireland 56 was 
appropriately adapted. 
 
Section 1 recorded patient satisfaction with services received at the time of consultation 
using 10 medical interview satisfaction questions 55, 56 and 'ease of access' to services using 
7 additional questions 62. 
 
Section 2 comprised 4 statements measuring patients' attitudes to physiotherapist and 
podiatrist independent prescribers (65,68) and 14 statements about the advice/information 
they may have received from physiotherapist and podiatrist independent prescribers/ non-
prescribers during the consultation including side effects, action of use and dose schedule and 
medicines adherence 55-57, 61. 
 
Section 3 employed the validated EQ-5D-5L quality of life profile measure of five dimensions 
(mobility, self-care, usual activities, pain, anxiety/ depression) rated on five levels (no problem 
to severe problem/ unable questionnaire 63. Although the standardized extended EQ-5D 
incorporates a vertical 20 cm visual analogue scale (VAS) rating scale, patient and public 
involvement group members consistently reported difficulty indicating numerical values for 
how they felt at any one time point. It was therefore decided to exclude this from the 
questionnaire.  
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Section 4 comprised 7 items related to general demographics in order to describe respondent 
characteristics including age, living arrangements, employment, ethnic group and educational 
attainment.  
 
Follow up Questionnaire 2: comprised of 5 questions relating to health resource use in 
addition to a second completion of the EQ-5D-5L asked over telephone. Patients were asked 
if they had, in the 2-month period following consultation received medicines 
prescribed/recommended by the physiotherapist and podiatrist independent prescribers/ 
non-prescribers, undergone diagnostic tests (e.g. radiology, blood tests), returned to the 
physiotherapist and podiatrist independent prescribers/ non-prescribers for follow-up 
treatment, been referred to other services/professionals, or received unplanned treatment 
for the same condition following the initial consultation (list of 10 potential services) (see 
Table 1). 
 
Data Analysis 
Quantitative data were entered on to SPSS© Version 22.  Descriptive statistics were used to 
summarise the data and reported where open text data (specifically in relation to medication 
details and requested tests from the observation diary) had been converted to numeric data. 
Patient satisfaction and ease of access to services were measured on a 5-point Likert scale or 
as Yes/No responses. The Likert scale responses were easily reducible to positive or negative 
responses. 
When assessing change in EQ-5D-5L descriptive health score from Patient Questionnaire 1 to 
Questionnaire 2, a paired t-test was used.  
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When comparing 2 subgroups for normally distributed outcomes (notably change scores from 
Questionnaire 1 to Questionnaire 2, such as for overall EQ-5D-5L score), an unpaired t-test 
was utilised.  
 
When comparing 2 subgroups (in particular prescribing and non-prescribing) for an ordinal 
outcome, a Mann-Whitney U test was utilised. When comparing 2 subgroups (notably 
Podiatry and Physiotherapy or prescribing and non-prescribing) for a categorical outcome, 
the Chi-Squared test was used, reverting to a Fisher’s Exact test in 2x2 cross tabulations if 1 
or more expected cell count was found to be < 5. 
 
Economic analysis:  
Seven resource implications of independent prescribers compared to non-prescribers were 
originally considered: rates of prescribing tests ordered; referrals to other health 
professionals; frequency of follow up; consultation duration; time spent discussing the 
patient with other colleagues; unplanned consultations for the same condition within two 
months of the index consultation.  Data were gathered through the observation diary, except 
for tests (from the retrospective audit) and unplanned consultations (from the patient follow 
up questionnaire). Group level comparisons of independent prescribers compared to non-
prescribers for physiotherapists and podiatrists were undertaken separately for each of the 
seven variables.  
 
The cost implications (British pounds 2015) of differences in consultation length and 
colleague’s time spent in discussion were examined by applying nationally valid unit costs 64. 
A comprehensive micro level costing analysis could not be conducted because data on tests 
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and unplanned consultations were only gathered for a sample of patients and insufficient 
details were available on medications, referrals and planned follow up to enable costs to be 
reliably ascribed.  Costs that could be estimated were considered in relation to outcomes 
(satisfaction with consultation, satisfaction with advice, changes in health-related quality of 
life (EQ-5D-5L) between baseline and follow up) in a simple cost consequences framework. 
 
Results 
Characteristics of participants 
i) PPs and case sites 
Seven matched pairs of sites, (3 podiatry and 4 physiotherapy) were recruited. Sites were 
based across 8 Academic Health Science Networks in England 
(https://www.ahsnnetwork.com/) , provided adult services, a mixed range of settings,  
including private practice (n=2), primary care (n=6), secondary care (n=6), social enterprise 
(n=2) and were well matched by professional role, care setting and agenda for change banding 
(see Table 2). All physiotherapist and podiatrist independent prescribers had been qualified 
for at least 12 months prior to data collection. A total of 488 patients were recruited: 243 
across the PP-IP sites with 245 across the NP-PP sites. 
Insert Table 2 here 
Nearly all consultations (n=474), both independent prescribers and to non-prescribers, were 
face to face (n=473, 99.8%), duration 2-203 minutes. There was considerable variation in the 
location of services: 39.2% (n=186) of consultations were provided in NHS hospital 
outpatients, 25.1% (n=119) NHS community clinics, 20.3% (n=96) private practice, 9.7% 
(n=46) general practice, 4.4% (n=21) social enterprise and 1.3% (n=6) community service.  Of 
the observed consultations 112 (23.6%) included a medicine related activity, where either a 
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new medication, repeat medication (same dosage) or repeat medication with a change to 
dosage was required, with patients requiring a total of 124 items of medicine (see Table 3).  
 
Insert Table 3 here 
Almost all medicines related activity within physiotherapy sites, both independent prescribers 
and  non-prescribers, was related to pain and movement control, either via pain medication 
or through injection therapy. There was one incident where a patient was advised to alter 
contraception use following surgery by an independent prescriber. A wider range of 
medication types were used by podiatrists, both independent prescribers and to non-
prescribers, the most common being anti-microbial/anti-fungal topical creams, antibiotics 
and pain medication. Patients requiring medicines recommended by non-prescribers, both 
podiatrists and physiotherapists, were subsequently referred to a medical doctor in the usual 
way.  
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Table 3: Consultations with medicines related activity  
Number of observed consultations  Physiotherapist IP Number 
of items 
Physiothe
rapist NP 
Number 
of items 
Podiatrist IP Number 
of items 
Podiatrist NP Number 
of items 
n=107 n=37 n=115 n=29 n=128 n=45 n=124 n=13 
Consultations with no medicines related 
activity 
75 n/a 87 n/a 93 n/a 114  
Consultations with medicines activity         
New medication  23 21 x 1 
 2 x 2   
3 x 1 
27 26 x 1 
1 x 2 
31 27 x 1 
3 x 2 
1 x 4 
10 7 x 1 
3 x 2 
Repeat medication (same dosage) 9 9 x 1 1 1 2 2x 2 0 0 
Repeat medication (dosage changed) 0 0 0 0 2 2 x 2 0 0 
Total number of consultations with 
medicines related activity 
n=32 n/a n=28 n/a n=35 n/a n=10 n/a 
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ii) Patients 
Demographic data (see table 4) were collected from 315/ 468 (67.3%) patients who 
consented to and returned patient questionnaire 1: 49.5% (n=156) were from prescribing 
and 50.5% (n=159) from non-prescribing sites. A lack of benchmark data with which to 
compare the patient data means it is not possible to confirm how representative our sample 
is with respect to the larger population. However, the samples, from the prescribing and 
non-prescribing group in this study were similar in terms of age, employment status, level of 
formal education, and ethnic group (p>0.05).  
Table 4: Patient characteristics 
  
Physiotherapy 
n (%) 
Podiatry 
n (%) 
Total 
n=number of 
responses 
% of total 
sample 
Professional group     
Which professional consulted 135 (42.86%) 180 (57.14%) 315 100% 
Gender   n=254  
Male 34 (30.4%) 55 (38.7%) 89 35% 
Female 78 (69.6%) 87 (61.3%) 165 65% 
Age                         
Physiotherapy group: n= 111, mean 59.7, SD 16.6, (range 17.6-100.98) 
Podiatry group: n=139, mean 67.1, SD 16.16, (range 16.17-94.32) 
Total: n=250, mean 63.8, SD 16.7 
Living arrangements   n=257  
Live alone 19 (17.4%) 32 (21.6%) 51 19.8% 
Live with other adult(s) 90 (82.6%) 94 (63.5) 184 71.6% 
Care home resident 0 22 (14.9%) 22 8.6% 
Type of accommodation   n=276  
Owner occupied house/flat 97 (82.2%) 104 (65.8%) 201 72.8% 
Privately rented house/flat 12 (1.02%) 12 (7.6%) 24 8.7% 
Local authority/housing 
association/cooperative 
9 (7.6%) 13 (8.2%) 22 8% 
Residential or care home, 
hospice 
0 29 (18.4%) 29 1.05% 
Employment group   n=262  
In paid or voluntary 
employment 
46 (41.1%) 40 (26.7%) 86 32.8% 
Unemployed/student/at 
home/sick 
15 (13.4%) 12 (8%) 
27 10.3% 
Retired 51 (45.5%) 98 (65.3%) 149 56.9% 
Educated beyond 18 years   n=274  
Yes 32 (27.4%) 51 (32.5%) 83 30.3% 
No 85 (72.6%) 106 (67.5%) 191 69.7% 
Ethnic group   n=283  
White 117 (96.7%) 160 (98.8%) 277 97.9% 
Other 4 (3.3%) 2 (1.2%) 6 2.1% 
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Follow up questionnaire 2:  A response rate of 73.7% (197/267) was obtained for 
questionnaire 2. This sample excluded the 175 participants from the first 4 sites (Sites 1, 2, 4, 
7) (see Table 2). Of the remaining 313 participants, 285 consented to follow-up, however 
contact details were incorrect or missing for 18 participants, leaving 267 eligible to 
participate.  
 
iii) Patient outcomes 
a) Satisfaction and access to services  
The majority of patients (75.9%, n=239) agreed that physiotherapists and podiatrists should 
be able to prescribe medicines for patients, however 23.2% (n=73) would prefer a doctor to 
prescribe.  Levels of satisfaction for the sample as a total were high, with over 60% positive 
agreement on all items other than ability to contact the service in an emergency (n=144, 
44.4%). Satisfaction with 17 specified aspects of the consultation and services provided by 
physiotherapists and podiatrists indicated a significantly higher level of satisfaction among 
the patients of physiotherapist and podiatrist independent prescribers than those of non-
prescribers in 8 instances (table 5).  
 
With respect to service access, patients of podiatrist independent prescribers were more 
satisfied with ‘the ease of making an appointment’ and ‘the ability to contact the service by 
phone or in times of emergency’ (see table 5) than patients of the non-prescribing podiatrists, 
with no notable difference evident in patients attending physiotherapist prescribers 
compared to patients of non-prescribing physiotherapists.   
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There was no effect on the remaining four items reporting on ease of access on the 
acceptability of: i) waiting time to obtain an appointment; ii) obtaining an appointment on a 
convenient day or hour; iii) waiting time or iv) seeing the physiotherapist or podiatrist at the 
appointed time between patients attending a physiotherapist or podiatrist independent 
prescriber when compared to those attending a non-prescribing physiotherapist or podiatrist.  
 
Insert Table 4 here 
Patients of a physiotherapist or podiatrist independent prescribers were more likely to 
receive medicines information or advice during the consultation (58 out of 146 (39.7%) vs 37 
out of 151 non-prescribing physiotherapist or podiatrist patients (24.5%); p=0.005), with 
varying levels of satisfaction reported (see table 6). Compared to patients of non-prescribing 
physiotherapist or podiatrists, patients of physiotherapist or podiatrist independent 
prescribers were significantly more likely to: ‘be told when’ and ‘how often’ to take their 
medicine, ‘intend to take their medicines’ and ‘find it easier to follow the physiotherapists’ 
advice’ (p≤ 0.05). 
Insert Table 6 here 
b) Quality of life- EQ-5D-L 
Indications at baseline were that patients who saw physiotherapist independent prescribers 
had lower generic quality of life than those seeing the non-prescribing physiotherapists, due 
to lower scores on the mobility dimension.  However, there was no statistically significant 
difference between physiotherapist or podiatrist independent prescribers and non-
prescribing physiotherapist or podiatrist groups on either individual items or overall EQ-5D-
5Lscore (p≥0.05) (Table 7, individual dimension scores not shown). 
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Quality of life overall scores in both physiotherapist and podiatrist independent prescribers 
and non-prescribing groups improved significantly between baseline and follow-up. 
Differences in change scores between the physiotherapist and podiatrist independent 
prescribers and non-prescribing physiotherapist or podiatrists, however, were not 
statistically significant (Table 7). The sample for which data at both time points were 
available was limited (n=116). 
Table 7: Overall EQ5D index score: baseline and follow-up 
 
 From the 129 
completers 
Baseline for 
116 with EQ5D 
in BOTH data 
sets only 
Follow-Up for 
116 with EQ5D 
in BOTH data 
sets only 
  
 Number of 
patients 
completing BOTH 
sets of EQ5D 
questions 
EQ5D-5L 
 
 
 
Mean (SD) 
EQ5D-5L 
 
 
Mean (SD) 
Change from Baseline 
(95% CI)*  
Paired 
t-test 
p-value 
PT IP 25 0.56 (0.31) 0.64 (0.27) 0.08 (-0.04 to 0.19) 0.194 
PT NP 28 0.73 (0.19) 0.73 (0.22) 0.001 (-0.07 to 0.07) 0.973 
PO IP 33 0.70 (0.26) 0.78 (0.20) 0.08 (0.003 to 0.16) 0.042  
PO NP 30 0.66 (0.26) 0.76 (0.28) 0.10 (0.03 to 0.16)  0.004  
All IP 58 0.64 (0.29) 0.72 (0.24) 0.08 (0.01 to 0.14) 0.019  
All NP 58 0.69 (0.23) 0.75 (0.25) 0.05 (0.003 to 0.10) 0.036  
All PT 53 0.65 (0.26) 0.69 (0.25) 0.04 (-0.03 to 0.10) 0.266 
All PO 63 0.68 (0.26) 0.77 (0.24) 0.09 (0.04 to 0.14) 0.001 
*[Positive change indicates mean improvement in health at Follow-Up] 
 
iv. Economic analysis 
 Amongst physiotherapists, the independent prescribers had significantly longer consultation 
duration than non-prescribers (27.6 vs 20.8 minutes) (Table 8).  Amongst podiatrists, the 
frequency with which medications i.e. a new medication, repeat medication (same dosage), 
or repeat medication (dosage changed) and tests were ordered were significantly higher in 
independent prescribers than non-prescribers (Table 8). There was a trend for consultation 
duration to be longer for independent prescribers (23.4 vs 19.9 minutes) (Table 8). 
Comparing physiotherapists and podiatrists, planning of follow up consultations was higher 
by podiatrist independent prescribers than physiotherapist independent prescribers, but no 
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significant differences were found between independent prescribers and non-prescribers 
within the professions. After removing unplanned consultations in the two months after the 
original consultation that were considered (by two independent reviewers) to be unamenable 
to treatment delivered in the index consultation, only four items of unplanned service 
utilisation remained across the whole sample of patients of physiotherapists and podiatrists, 
all of which were related to pain relief (Table 8). 
Costs of consultations: Difference in costs of consultation duration of independent prescribers 
compared to non-prescribers for physiotherapist and podiatrist groups were based on  
Agenda for Change (AfC) band 8a, which was the most frequent grade of physiotherapist and 
podiatrist independent prescribers in the study, i.e. £70 per hour 64. Compared to the cost of 
a non-prescriber consultation, the independent prescriber consultation was, on average, 
more costly by £7.95 for physiotherapists (£24.30 vs £32.25) and £8.62 (£19.69 vs £28.31) for 
podiatrists.  The salary of a grade 9 professional is twice that of grade 8a, so at that higher 
level, the differences in the cost of consultations between independent prescribers and non-
prescribers would be doubled. Use of grade 7 instead of grade 8a would reduce the 
differences between independent prescribers and non-prescriber by about £1.20 per 
consultation. Amongst the podiatrists, the independent prescribers were at band 7 (advanced 
/ team leader), 8a (principal) and 9 (consultant); two of the non-prescribers were band 9 and 
the third was band 6 (specialist).  Participating physiotherapists were all band 8a, except one 
non-prescriber (grade 8c), and one independent prescriber (grade 7). 
 
Costs could not be estimated for the other elements of activity that might differ between 
independent prescribers and non-prescribers due to data availability problems.  Information 
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on tests ordered were drawn from a small sample of records (n=max 15 per site) in each site 
(the audit); reporting of the type and dose of new medications, referrals and frequency of 
planned follow up was incomplete.  
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Table 8 Comparison of independent prescribers and non-prescribers, by profession, on variables used in the cost analysis 
 Number of medications required= new medication + repeat medication (same dosage) + repeat medication (dosage changed) 
 
Professional 
group 
Prescribing 
status 
 Number of 
medications 
required 
(Observation Q6) 
Number of tests 
requested / 
patient 
(Sample audit)  
Consultation time 
in minutes / 
patient 
(Observation Q1) 
Discussions with 
colleagues in minutes/ 
per patient (Observation 
Q9,10) 
 x Patients receiving 
referral (not for 
tests) (Observation 
Q11) 
Patients with 
planned follow up 
(Observation Q15) 
Patients reporting verified 
unplanned consultations 
within 2 months (Patient 
questionnaire) 
PHYSIO- 
THERAPY 
Independent 
prescriber (IP) 
N 107 42 107 107 N 107 107 47 
Missing 9 74 9 9 Yes N 32 54 (8 by phone) 1 
N, % of zeros 75, 70.1% 32, 76.2% 0 88, 82.2% Yes % 29.9% 50.5% 2.1% 
Mean 0.327 0.262    27.64 1.802        
SD 0.546   0.497    14.10 5.585        
Median 0 0 24 0     
IQR 0 to 1 0 to 0.25 18 to 34 0 to 0     
Non 
prescriber 
(NP) 
N 115 44 115 115 N 115 115 46 
Missing 7 78 7 7 Yes N 34 51 (1 by phone) 2 
N, % of zeros 87, 75.7% 33, 75.0% 0 114, 99.1% Yes % 29.6% 44.3% 4.3% 
Mean 0.252  0.250    20.83 0~        
SD 0.456 0.438    10.46 0~        
Median 0 0 19 0     
IQR 0 to 0 0 to 0.75 14 to 28 0 to 0     
Significant difference (p) MWU 0.336 MWU 0.949 MWU 
<0.0005 
MWU <0.0005  Chi Sq 0.956 Chi Sq 0.361 FE 0.617 
           
PODIATRY Independent 
prescriber (IP) 
N 128 24 128 128 N 128 128 57 
Missing 5 109 5 5 Yes N 17 110 (0 by phone) 0 
N, % of zeros 93, 72.7% 17, 70.8% 0 109, 85.2% Yes % 13.3% 85.9% 0% 
Mean 0.328 0.375    24.27 0.976        
SD 0.616  0.647    24.32 2.682        
Median 0 0 16 0     
IQR 0 to 1 0 to 1 11 to 27.75 0 to 0     
Non 
prescriber 
(NP) 
N 124 32 123 124 N 124 124 47 
Missing 3 95 4 3 Yes N 6 111 (7 by phone) 1 
N, % of zeros 114, 91.9% 32, 100% 0 111, 89.5% Yes % 4.8% 89.5% 2.1% 
Mean 0.105 0   16.88 0.726        
SD 0.379 0    9.86 2.867        
Median 0 0 16 0      
IQR 0 to 0 0 to 0 10 to 23 0 to 0     
Significant difference (p) MWU 0.001 MWU 
<0.0005 
MWU 0.073 MWU 0.349  Chi Sq 0.20 Chi Sq 0.387 FE 0.452 
25 
 
Discussions with colleagues:  The independent prescribers in the physiotherapist group 
consulted colleagues about patients significantly more often than the non-prescribers 
(17.8% vs 0.9% of consultations), and most discussions were with medical colleagues, 
averaging 9.5 minutes per discussion (Table 9). 
 
Podiatrists held discussions with colleagues for >10% of consultations (14.8% IPs, 10.5% NPs, 
(Table 9)), for around 7 minutes. Independent prescribers discussed a higher proportion of 
patients with medical colleagues, than a colleague from the same profession, thereby likely 
to be incurring higher costs.  However, information on colleagues consulted was not precise, 
so calculations were indicative only. Some podiatrists were band 9 (consultant), so reporting 
discussions with ‘same’ professional would imply higher costs than are indicated in the table, 
which are based on AfC band 8a. 
Table 9 Discussion with colleagues about patient 
Professional 
group 
Prescribing 
status 
Number 
and % of 
all patients 
seen for 
whom 
discussion 
occurred 
with 
colleague 
Mean (SD) 
minutes in 
discussions 
with 
colleague   
per patient 
Discussion 
with same  
professional  
n, mean (SD) 
minutes 
Same 
colleague  
cost / 
discussion* 
(£, 2015) 
Discussion 
with  
medical 
professional  
n, mean(SD) 
minutes 
Medical 
colleague 
cost / 
discussion* 
(£, 2015) 
PHYSIOTHERAPY Independent 
prescriber 
19 (17.8%) 10.61 (9.68) 3,  19.5 (14.8) £22.75 16,  9.5 (8.9) £21.69 
 Non 
prescriber 
1 (0.9%) 0 (n/a) 1,  time 
missing 
Not known 0,  n/a 0 
 Significant 
difference 
p<0.0005# n/a     
        
PODIATRY Independent 
prescriber 
19 (14.8%) 6.89 (3.20) 11,  6.8 (3.6) £7.93 8,  7.0 (2.8) £15.98 
 Non 
prescriber 
13 (10.5%) 6.92 (6.14) 12,  7.3 (6.3) £8.52 1,  3.0 (0.0) £6.85 
 Significant 
difference 
p=0.299~ p=0.493^     
# Fishers Exact test; ~ Chi squared test; ^ Mann Whitney U test 
* Unit costs of health and social care 2015 (Curtis and Burns 2015), pro rata based on £70/ hour for same professional i.e. AfC 
band 8a, as in Ec2 above, and £137/ hour for medical consultant 
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Cost implications: The available data suggest that for both physiotherapists and podiatrists in 
this study, care delivery by independent prescribers is more resource intensive and costly 
than non-prescribers due to longer consultations for physiotherapists and taking more time 
of colleagues to discuss patients.  Whilst not costed, podiatrist independent prescribers had 
higher frequency of ordering medications and tests than non-prescribing podiatrists. Analysis 
of the changes in self-reported health status between baseline and 2 months follow up using 
EQ-5D-5L found no difference in change scores of independent prescribers and non-
prescribers for either physiotherapists or podiatrists, but these data were only available for a 
small sample of participants.  
Discussion 
 
This is the only known national evaluation of physiotherapist and podiatrist independent 
prescribers in the UK or the world, and the first to adopt a comparative case study design to 
compare outcomes and costs for patients managed by physiotherapist and podiatrist 
independent prescribers/ non-prescribers.  Unlike nurses and pharmacists, where prescribing 
has been explored in some detail using self-reported outcomes 26, 47, 54, there is a dearth of 
equivalent information in the allied health professions, including either physiotherapy and/ 
or podiatry 29, 35 and/ or studies adopting direct observation of outcomes26.  Our study 
demonstrates that care provided by physiotherapist and podiatrist independent prescribers 
is equivalent, in terms of quality of life and patient satisfaction, to care provided by non-
prescribing physiotherapists with prescribing undertaken by doctors. Independent 
prescribing by physiotherapists and podiatrists was found to be effective, and highly 
acceptable, with higher levels of patient satisfaction in some aspects of medicines information 
also reported than for non- prescribers.  
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Importantly, it appears that physiotherapist and podiatrist independent prescribing is 
developing in line with original policy intention to improve access  to medicines and quality 
of care across a range of settings 65-67.  The evidence generated in this study demonstrates 
that physiotherapist and podiatrist independent prescribers can provide a high standard of 
care.  Extending non-medical staff, such as physiotherapists’ and podiatrists’, scope of 
practice to include independent prescribing is key to supporting effective delivery of the NHS 
Long Term Plan 9, 49, 68, and creating a step change in developing the capacity and capability 
of the workforce to deliver innovative models of service delivery 4, 9. The severity of the 
workforce deficit makes changes, such as the increased level of clinical autonomy, associated 
with independent prescribing an attractive option to commissioners who seek to address gaps 
in service delivery. As the world leader in extending prescribing rights to nurses, pharmacists 
and allied health professions the findings are of significant importance to international policy 
makers who seek to learn from the pioneering advancement of prescribing rights in UK 25, 28 
to inform their own approach to addressing the workforce deficit.  
 
Internationally it is now common for physiotherapists, nurse practitioners, pharmacists, social 
workers, and psychiatric nurses to be located within extended primary care teams 69 with 
plans to extend this further recently announced 9, 11.  Nearly 50% of appointments in UK 
general practice are for example, already provided by non-medical staff, i.e. nurses, 
pharmacists and allied health professionals 9, 70. In addition to the current shortage of 2,500 
general practitioners,  this is important for several reasons : i) the current deficit in primary 
care looks set to continue 71, 72; ii) the recent proposal for home visits to be removed from the 
GP contract, and iii) the government pledge to create 50 million more GP appointments year 
by 2024/25 72, 73. As the third largest workforce in health and care in England, allied health 
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professionals have, through the introduction of  a further 20,000 non-doctor roles in primary 
care 74,  great potential to contribute to transforming care and ensuring ongoing access to 
medicines 11. 
Having a robust  economic evaluation of physiotherapist and podiatrist independent 
prescribing is particularly important, given that identifying a sustainable solution that i) 
improves the worldwide deficit of health workers, and  ii) makes best use of limited resources 
is essential to ensuring ongoing access to medicines 9, 11. Our cost appraisal from the case sites 
suggests that physiotherapist and podiatrist independent prescriber care delivery is more 
resource intensive than non-prescribing physiotherapists and podiatrists.  This arises through 
longer consultation duration, more ordering of medicines and tests (podiatrists) and more 
discussions with colleagues (physiotherapists). These costs, however, need to be considered 
in relation to benefits, particularly clinical outcomes, many of which could not be measured 
in this study. Only a limited economic analysis was possible meaning that the findings should 
be treated with caution. Whilst the original intention had been to undertake a patient level 
micro costing analysis, data deficiencies limited what could be included. Further research is 
required to understand how team configuration affects care delivery, patient outcomes and 
costs.   
The most complete data were available for consultation duration, and the calculation of 
associated costs showed independent prescribers to incur slightly higher consultation costs 
than non-prescribers in both the podiatrist and physiotherapist groups (£8.62 and £7.95 
respectively). It is important to note however that consultation duration and associated costs 
may simply be driven by professional differences and clinic practices. The complexity of these 
arrangements means that the differences in cost could equally reflect service differences 
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which would exist regardless of independent prescribing status. Furthermore, the time spent 
in discussion with colleagues may reflect the multi-professional service that many case sites 
provided.  Multi-professional, or team-working is a fundamental component of health care 
delivery in the UK and central to current government policy 75-77. There is increasing emphasis 
on establishing systems, rather than single episodes of care, that dissolve traditional 
boundaries 78, 79 to support the increasing number of people with long-term conditions.  
 
There is limited evidence available with which to compare our study findings 26, 35, 45, 46, 80. 
Despite positive findings that non-medical prescribing is safe, and provides beneficial clinical 
outcomes  26, 28, 54, the impact on the health economy, as reported in two recent systematic 
reviews examining clinical and cost effectiveness, remains unclear 45, 46, 80.  The authors, as in 
this study, highlight the difficulty in separating non-medical prescribing effects from the 
contributions of healthcare team members, and a lack of adequately powered randomised 
controlled trials examining non-medical prescribing across clinical specialities, professions 
and settings 25, 45. Given that extended prescribing rights to nurses, pharmacists and allied 
health professions offers a sustainable approach to improving the global workforce deficit, 
there is a pressing need to establish economic benefits, or otherwise of non-medical 
prescribing to inform future international policy developments. A different approach, 
involving highly targeted specific outcomes, and or longitudinal studies is therefore required.  
The development of a minimum data set of important outcome measures for non-medical 
prescriber assessment would as Noblet et al. suggests 45, be highly beneficial, and generate 
the required evidence to evaluate the overall benefit of non-medical prescribing and inform 
future developments in the UK and around the world.  
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Strengths and limitations 
In the first study to explore allied health professional prescribing, the 14 case sites supported 
an in-depth evaluation and comparison of physiotherapist and podiatrist independent 
prescribers to non-prescribers in a range of care settings. Use of multiple methods of data 
collection, including an observational component, strengthens the trustworthiness of the 
findings. Physiotherapist and podiatrist independent prescriber participants were selected 
from a larger sample (n=70) who completed a trainee physiotherapist and podiatrist 
independent prescriber survey and indicated that they would be willing to be involved in 
further research 52. 
Despite challenges in matching sites, given the diversity of service settings, roles, and patient 
needs, between and within the two professions, patient characteristics indicated good 
matching on most factors. For future research, matching at a patient/condition level would 
ensure a comparative sample. Additionally, as patients were predominantly retired, house 
owners, and lacked ethnic diversity, reflecting study locations, caution must be applied with 
respect to generalizing the findings to other groups of the population.  Furthermore, there 
are limitations and methodological challenges associated with using the same evaluation 
measures on two different professional groups for whom separate measures might have been 
more appropriate. The economic analysis was constrained as described above. An analysis of 
effectiveness was not possible because it was not feasible to collect data on specific indicators 
for change across the wide variety of conditions treated within physiotherapist and podiatrist 
consultations. Our ability to link each of the various aspect of patient data (i.e. observation, 
questionnaires, record audit) was also very limited as patients, in line with good ethical 
practice, had the option to select which aspects of data collection they agreed to.  As a result, 
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it was not possible to match patients across the different data sets, or to complete some of 
the intended analysis.  
Conclusions 
This study provides new knowledge about physiotherapist and podiatrist independent 
prescribing, the high level of care and patient satisfaction they provide. Given that extending 
prescribing responsibilities to nurses, pharmacists, and allied health professionals is 
increasingly being recognised as effective way to alleviate shortfalls in the global health 
workforce and ensure ongoing access to prescription medicines around the world this is 
important. PP-IP care delivery was found to be more resource intensive than NP-PP. However, 
this study is limited, and findings needs to be verified through further research, including a 
full economic analysis. A more focussed longitudinal exploration within each profession with 
targeted outcome measures would enable a more robust comparison of the impact of 
physiotherapist and podiatrist independent prescribing across the United Kingdom and 
inform further developments around the world.  
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Tables 
Table 1 Summary of data collection arrangements and instruments 
 
Category of 
data  
Method of data 
collection 
Timing of collection Items and instruments Piloting 
1) Characteristics 
of PPs & sites 
 
i) Structured interview 
and site visit 
 
Prior to observation 
period 
Setting and geographic location 
 
PPs profile: Age, gender, highest educational 
qualification, salary/band, full/part time status, job 
title/role;  
 
Service Information: service description & patient 
profile, single or multi-professional team, other NMPs 
in team 
Interview schedules were reviewed 
by research team and project 
advisory group.  Main interviewer 
(JE) was buddied by experienced 
team member (KS) for first two 
interviews in order to provide 
guidance and clarify and address 
any issues with the interview 
schedule.   
 
Following this, minor revisions were 
made to improve the flow of 
questions. 
 
2) Patient 
characteristics 
 
i) Patient questionnaire 1 
& 2 
Post consultation and 2 
months following 
Socio-demographics: age, gender, living arrangements; 
accommodation, employment; education; ethnicity 
Q1: Patients (n=5) completed and 
commented on ease of 
comprehension, length and time. 
Based on comments no refinements 
were made.  
Q2: piloted concurrently at first site 
(case-site 3). After first 10 
completed, ease of use, consistency 
and question completion rate were 
discussed with no amendments or 
changes required. 
 
3) Patient 
reported 
outcomes 
 
i) Patient questionnaire 1  
 
 
 
 
 
Post consultation  
 
 
 
 
 
Patient satisfaction: with consultation, advice and 
medicines information comprised subscales from 
several validated tools (total 24 items):  
i) Consultation Satisfaction Questionnaire  i.e. 
‘professional care’, ‘perceived time’ and ‘overall 
satisfaction’ and ii) Medical Interview Satisfaction 
Formal piloting was undertaken in 
January 2015 in a secondary care 
based rheumatology outpatient 
clinic (not designated as a site). Five 
completed questionnaires were 
returned with comments indicating 
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ii) Patient questionnaire1 
and 2  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Post- consultation and 2 
months following 
consultation (excluding 
1st 
 four sites) 
 
Survey (MISS) 60, 61 ‘compliance intent’ (10 items) & for 
patients who received medicines information or advice 
questions from PP iii) Satisfaction with Information 
about Medicines (SIMS) Scale 55 e.g. dose schedule, how 
medicine works, side-effects, and medicines adherence) 
55-57, 61 (14 items). 
 
Service Satisfaction: was measured by 7 items on ease 
of access to services from the outpatients' opinion of 
quality of hospital departments questionnaire 62- 7 
items. 
 
Attitudes towards PP-IP 56, 81- 4 items. 
 
6 point Likert scales (strongly disagree to strongly 
agree) used for all items 
Quality of life validated EQ-5D-5L 63 comprising 5 
dimensions, from independent – dependent, with 5 
weighted levels affording a single index value score. (i.e. 
mobility, self-care, usual activities, pain/discomfort and 
anxiety/depression) 
 
that content, layout and design was 
comprehensive and completion 
time was of acceptable length, 
ranging from 9-15 minutes. 
 
 
 
 
 
 
 
 
 
Questionnaire 2 was implemented 
following data collection completion at 
the first four sites, and was piloted 
concurrently at the first site visited (site 
3) after its approval. After the first 10 
completed questionnaires, ease of use, 
consistency and question completion 
rate were discussed at team meetings; 
no amendments or changes were 
required.    
 
4) PPs activities  i) Observation diary 
completed by researcher 
 
 
 
 
 
 
 
 
 
 
 
 
 
Real-time service 
delivery up to 5 working 
days (37 hours) 
 
 
 
 
 
 
 
 
 
 
 
 
Using a Microsoft Access© custom built electronic diary 
based on previous validated tools82-84, a researcher 
recorded details of the model of service provision and 
MMA (including outcome and prescribing actions) during 
each observed consultation.  
Model of service provision: Consultation duration (in 
minutes); type of consultation (face to face, telephone, 
email) and appointment (initial, follow-up, emergency), 
service & referral source (e.g. NHS in/outpatient, 
community, GP, social enterprise, private). Other work 
activities in relation to care included referrals made (to 
whom and how), discussion with colleagues, time spent 
in discussions with colleagues and review arrangements. 
Details of 8 observed consultations 
were recorded and downloaded into 
Microsoft Excel©. Data were found 
to be comprehensive, and the 
template layout/design revised 
following team discussion data. 
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ii) Prescriptions  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Real-time service 
delivery up to 5 working 
days (37 hours) 
 
 
 
 
 
 
 
MMA i) outcome: whether a new medication was 
required; decisions to alter, stop, or make no change to 
existing medications; or decision to repeat prescribe 
previous item(s);  
ii) prescribing actions; decision to recommend OTC 
product; recommend to Dr, other prescriber  or via 
hospital notes prescription is required; adjust dose/drug 
according to pre-agreed protocols; (i.e. PGD; PSD, 
exemptions); whether provided advice to patients about 
medicines (i.e. how it works, when  to take and side-
effects); medication details (i.e. name, dose, duration, 
formulation) 
Questions were fixed option and/or free text. 
 
All prescriptions issued by PP-IPs during observed 
consultations were collected and assessed based on 
previous work 85-87 and guidelines for prescription 
writing in the BNF 88 (i.e. accuracy, legibility, correct use 
of terminology, whether medicines were prescribed 
generically, preparation details, dose, dose frequency, 
length of treatment, and instructions regarding 
frequency, location and application of topical 
treatments). 
 
 
 
 
 
 
 
 
 
 
There was no piloting of the 
assessment tool as it had been used 
in previous studies 41, 89. 
 
5) Resource 
implications and 
costs 
 
i) Interviews with PPs 
 
 
 
Prior to baseline data 
collection 
 
 
Grade/ banding of each of the PPs in the study.  (as reported above) 
 
 
 
ii) Observation diary 
completed by researcher 
 
Real-time service 
delivery up to 5 working 
days (37 hours) 
 
Six items related to consultations with individual 
patients were also examined for differences between 
PP-IPs and NP-PP-NPs 
-number and duration of consultations 
- frequency & duration of discussions with colleague or 
other professional regarding patient’s medication 
-frequency of new medications 
-frequency of referrals and follow-up consultations  
 
(as reported above) 
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iv) Patient record audit 
 
Clinical records 2 
months following 
consultation. 
A maximum of 15 
patients per site were 
selected. 
Requested investigations, tests (e.g. BP, bloods, x-ray, 
MRI scan, CT, urine, sputum etc.)  and referrals and 
services used relevant to the presenting complaint (i.e. 
case site PP, consultant specialist, clinical nurse 
specialist, GP, GP based nurse/ nurse practitioner, 
community nurse pharmacists, social services, other 
healthcare professionals) other hospital outpatients, 
hospital admissions, and number of in-patient days, 
A&E visits etc.  
 
Audit tool: was piloted on 8 sets of 
medical records. Concerns were 
raised about quality of available 
data and that retrospective data 
collection could present difficulties 
with potential incomplete data. 
Following data collection at first 
four sites an amendment to the 
study protocol, as previously 
described was made. 
iii)Patient questionnaire 
2 
 
2 months following 
consultation (excluding 
first 4 sites) 
 
Self- report use of health services for PP related issues 
in the previous 2 months including:  tests received, 
referrals, follow-up consultations, un-planned 
consultation; visits or contact with GPs, clinical nurse 
specialist, pharmacists, social services, other healthcare 
professionals, hospital outpatient clinics, A&E visits, 
hospital admissions, and number of inpatient days 
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Table 2: Characteristics of the sites and Physiotherapists and Podiatrists 
Pair Case 
study 
site 
No. 
Patients 
Recruited 
Type of 
PP 
Job Title Setting Location in England * Age Salary 
band 
Full or 
part time  
<30 hrs in 
practice 
Education 
highest 
Single or 
multi-
professional 
team 
Patient 
questionna
ire 1 
Follow up- 
Patient 
Questionna
ire2 
Prescriptions 
1 1 49 PO-IP General/Private  Private  London 71 8a 
 
Full time Doctorate single 40 N/A 0 
2 46 PO-NP General/Private  Private London 47 12 Full time Masters single 35 N/A n/a 
2 3 33 PO-IP Specialist 
 
Secondary 
care, NHS 
In/outpatient 
Wessex 41 7 Full time Masters multi-
professional 
22 19 6 
8 37 PO-NP Specialist 
 
NHS primary 
& secondary 
(& private) 
Kent, Surrey, Sussex 39 6 Full-time Degree single 25 22 n/a 
3 10 51 PO-IP Surgeon/consultant   NHS 
secondary (& 
private) 
Oxford 59 9 Full time Masters multi-
professional 
32 38 3 
6 42 PO-NP Surgeon/consultant   NHS 
secondary 
North East &  
North Cumbria 
47 9 Part-time Masters multi-
professional 
26 23 n/a 
4 7 6 PT-IP Specialist Community London 31 7 Part-time Masters multi-
professional 
25 N/A 0 
4 11 PT-NP Specialist NHS Primary, 
Community 
care 
 
Kent, Surrey, Sussex 47 8a Full time Masters multi-
professional 
25 N/A n/a 
5 9 42 PT-IP Specialist Primary, 
community 
Social 
enterprise 
Kent, Surrey, Sussex 46 8a Full time Diploma multi-
professional 
2 2 3 
5 38 PT-NP Surgeon/consultant   Tier 2 NHS ESP 
assessment 
service 
Wessex 42 8a Part-time Doctorate multi-
professional 
6 3 n/a 
6 11 41 PT-IP Specialist Acute 
Foundation 
Trust 
Northwest coast 58 8a Full time Masters multi-
professional 
27 29 0 
12  35 PT-NP Surgeon/consultant   NHS 
secondary 
care 
Kent, Surrey, Sussex 48 8c Full time Masters multi-
professional 
19 23 n/a 
   7 
13 21 PT-IP Specialist NHS primary 
& community  
Social 
enterprise 
Kent, Surrey, Sussex 52 8a Full time Masters multi-
professional 
8 16 3 
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Job title: Surgeon/Consultant (consultant physiotherapists, consultant podiatric surgeons) General/Private (physiotherapists practitioners, physiotherapists, podiatrists) 
Specialist (e.g. Clinical specialist physiotherapists, extended scope physiotherapist clinical specialist podiatrists, clinical lead or senior podiatrists) 
 
 
  
14 36 
 
PT-NP Specialist Primary & 
community 
Social 
enterprise 
Kent, Surrey, Sussex 38 8a 
 
Full time Masters multi-
professional 
23 20 n/a 
Tota
ls 
 488          315 195 15 
47 
 
Table 5 Patient views and experience of satisfaction with care received from physiotherapist or podiatrist 
Patient views and experience of consultation with 
physiotherapist or podiatrist  
 
(R) indicates reverse score item 
 
Physiotherapist 
Independent 
Prescriber (n=62) 
Physiotherapist  
Non-prescriber 
 
(n=73) 
Mann- 
Whitney 
U-test 
Podiatrist  
Independent 
Prescriber (n=94) 
Podiatrist  
Non-prescriber 
 
(n=86) 
 Total 
n=315 
Strongly Agree/Agree 
(compared with strongly 
disagree/disagree/no opinion) 
Strongly Agree/Agree 
(compared with strongly 
disagree/disagree/no opinion) 
Strongly Agree/Agree 
 
n % sample n % 
sample 
p* n % 
Sample 
n % 
sample 
P * n % 
1. Overall I was satisfied with the consultation from 
this physiotherapist or podiatrist 
59 95.1% 
 
67 91.2% 0.280 85 90.4% 80 93.0% 0.281 291 92.4% 
2.The physiotherapist or podiatrist was very careful 
to check everything when carrying out my care 
60 96.8% 69 94.5% 0.092 82 87.2% 77 89.5% 0.367 288 91.4% 
3.I will follow the advice of this physiotherapist or 
podiatrist because I think she/he is right 
59 95.1% 64 87.7% 0.021 81 86.2% 75 87.2% 0.020 279 88.6% 
4.The time I was able to spend with the 
physiotherapist or podiatrist was a bit too short (R) 
46 74.2 % 61  83.6% 0.807 68 81.0%  59 68.6 % 0.333  234 74.3%  
5.The physiotherapist or podiatrist explained the 
reasons for the advice given 
56 90.3% 67 91.2% 0.150 79 94.0% 72 83.7% 0.711 274 87.0% 
6.Some things about the consultation with the 
physiotherapist or podiatrist could have been better 
(R) 
46 74.2 % 53 63.0 % 0.166 68 72.3% 60 69.8% 0.120  227 72.1% 
7.The physiotherapist or podiatrist listened very 
carefully to what I had to say 
57 91.2% 68 93.2% 0.344 79 94.0% 74 86.0% 0.330 278 88.3% 
8.I understand my treatment much better after 
seeing the physiotherapist or podiatrist 
54 87.1% 54 74.0% 0.025 68 72.3% 61 70.9% 0.164 237 75.2% 
9.The physiotherapist or podiatrist was interested in 
me as a person not just my illness 
50 80.1% 56 76.7% 0.033 77 81.9% 65 75.6% 0.152 248 78.7% 
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* p based on Mann Whitney U test using 5-point Likert Scale; for ease of interpretation, the table only displays for each item the number of patients who indicated a positive response (i.e. 
Strongly Agree/Agree or Strongly Disagree/Disagree for negatively paraphrased items (R) ) – all corresponding percentages relate to the entire subgroup at the top of the column i.e. 
interpreting no response to the specific item as a lack of a positive response.  
 
 
  
Patient views and experience of consultation with 
physiotherapist or podiatrist  
 
(R) indicates reverse score item 
 
Physiotherapist 
Independent 
Prescriber (n=62) 
Physiotherapist  
Non-prescriber 
(n=73) 
Mann- 
Whitney 
U-test 
Podiatrist  
Independent 
Prescriber (n=94) 
Podiatrist  
Non-prescriber 
(n=86) 
 Total 
n=315 
Strongly Agree/Agree 
(compared with strongly 
disagree/disagree/no opinion) 
Strongly Agree/Agree 
(compared with strongly 
disagree/disagree/no opinion) 
 
Strongly Agree/Agree 
 
n % sample n % 
sample 
P* n % 
sample 
n 
% 
sample 
P * n % 
sample 
10.I am NOT completely satisfied with the advice received 
from this physiotherapist or podiatrist (R) 
56 90.3% 61  83.6% 0.019  75 79.8% 67 78.0 % 0.455  249 79.0%  
11.It was easy to make an appointment with the 
physiotherapist or podiatrist   
35 56.5% 49 67.1% 0.900 74 78.7% 60 69.8% 0.028 218 69.2% 
12.There was an acceptable time lapse to obtain an 
appointment 
30 48.4% 43 58.9% 0.759 67 71.3% 57 66.3% 0.378 197 62.5% 
13.It was possible to obtain an appointment on a convenient 
day or hour 
40 64.5% 49 67.1% 0.695 70 74.5% 62 72.1% 0.067 221 70.2% 
14.I can contact someone in the service by phone for help or 
advice in case of problem 
38 61.2% 47 64.4% 0.881 70 74.5% 56 65.1% 0.020 211 67.0% 
15.In an emergency I can get a quick appointment/consultation 
at this service 
19 30.6% 25 34.2% 0.177 60 63.8% 36 41.9% 0.001 140 44.4% 
16.I saw the physiotherapist or podiatrist   at the appointed 
time 
42 67.7% 62 84.9% 0.111 74 78.7% 73 84.9% 0.952 251 79.7% 
17.The waiting time was acceptable   
 
45 72.5% 64 87.7% 0.088 80 85.1% 71 82.6% 0.494 260 82.5% 
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Table 6 Patient views and experience of medicines management advice and information provided by physiotherapist or podiatrist 
Patient views and experience of medicines 
management advice and information 
provided by physiotherapist or podiatrist  
 
 
 
 Physiotherapist 
Independent 
Prescriber  
(n=27) 
Physiotherapist  
Non-prescriber 
 
(n=24) 
Mann- 
Whitney 
U-test 
Podiatrist  
Independent 
Prescriber 
 (n=31) 
Podiatrist  
Non-prescriber 
(n=13) 
Mann- 
Whitney 
U-test 
Total 
 Strongly Agree/Agree 
 
Strongly Agree/Agree Strongly Agree/Agree 
N 
(excluding 
not 
applicable^ ) 
n %  n % 
 
p* n % 
 
n % 
 
p* n % 
1. The physiotherapist or podiatrist gave me 
time to clarify questions I may have had 
about my medicine 
84 24 96.0% 19 86.4% 0.627 21 84.0% 11 91.7% 0.901 75 89.3% 
2. The physiotherapist or podiatrist told me 
when to take my medicine 
64 11 73.3% 6 40.0% 0.030 19 82.6% 9 81.8% 0.719 45 70.3% 
3. The physiotherapist or podiatrist told me 
how often I should take my medicine  
61 12 85.7% 5 35.6% 0.002 19 86.4% 9 81.8% 0.835 43 70.5% 
4. The physiotherapist or podiatrist 
provided me with information on the 
purpose of my medicine 
75 16 73.7% 14 70.0% 0.547 19 82.6% 11 84.6% 0.549 60 80.0% 
5. The physiotherapist or podiatrist 
provided me with information on how to 
use my medicine 
59 11 73.3% 5 45.5% 0.062 16 80.0% 10 91.0% 0.608 42 71.2% 
6. I expect that it will be easy to follow the 
physiotherapist's or podiatrist's advice 
about my medicine 
68 12 75.0% 10 66.7% 0.181 22 91.7% 11 84.6% 0.346 57 83.8% 
7. The physiotherapist or podiatrist told me 
the name of my medicine 
71 17 85.0% 9 60.0% 0.178 18 75.0% 9 75.0% 0.354 53 74.6% 
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Patient views and experience of medicines 
management advice and information provided by 
physiotherapist or podiatrist  
 
 
 
 
Physiotherapist 
Independent 
Prescriber  
Physiotherapist  
Non-prescriber 
 
Podiatrist  
Independent 
Prescriber 
Podiatrist  
Non-prescriber 
 Total 
 Strongly Agree/Agree 
 
Strongly Agree/Agree 
 Strongly 
Agree/Agree 
N 
(excluding 
not 
applicable^
) 
n %  n 
% 
p* n 
% 
 
n 
% 
 
p* n % 
8. The physiotherapist or podiatrist explained 
the side effects of my medicine 
63 11 68.8% 12 70.6% 0.578 13 59.1% 5 50.0% 0.443 41 65.0% 
9. I would have liked to have received more 
information about my medicine from the 
physiotherapist or podiatrist  # 
73 3 13.6% 3 17.6% 0.438 0 0.0% 3 25.0% 0.288 9 12.3% 
10. The physiotherapist or podiatrist provided me 
with information on what to do if I missed a 
dose of my medicine 
48 3 25.0% 3 27.3% 0.795 3 21.4% 1 9.1% 0.274 10 20.8% 
11. It may be difficult for me to do exactly what 
the physiotherapist or podiatrist told me to 
do in relation to my medicine  # 
56 0 0.0% 1 9.1% 0.038 5 23.8% 1 9.1% 0.832 7 12.5% 
12. I'm not sure it will be worth the trouble to 
take the medicine advised by the 
physiotherapist or podiatrist  # 
62 2 13.3% 1 8.3% 0.298 1 6.7% 1 8.3% 0.570 
 
5 8.1% 
13. Receiving a prescription for medicine from my 
physiotherapist or podiatrist reduced my 
waiting time today 
40 4 30.8% 1 16.6% 0.919 6 46.1% 6 75.0% 0.446 17 42.5% 
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^ those patients who did not respond “Yes” to the preceding question “During the consultation today, did the physiotherapist or podiatrist prescribe and/or give you advice and information 
about medicines(s) ?”. 
*p-value based on Mann Whitney U test utilising the original 5 point Likert scale; for ease of interpretation, the table only displays for each item the number of patients who responded 
Strongly Agree/Agree.  
Note that for items labelled # this may not be regarded as a positive response.  
 
 
 
 
 
 
 
14. I am likely to take the medicine prescribed for 
me today 
47 7 36.8% 2 28.5% 0.022 13 72.2% 11 100.0% 0.204 33 70.2% 
